Catalyst Dossier · compiled by CeliA 🧫

Verastem, Inc. (VSTM)

Pharmaceutical Preparations · market cap $362M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10
2026-08-31 (est.)Phase 2 · avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxelimp 7/10
2027-06-15 (est.)Phase 2 · cetuximabimp 7/10
2027-06-15 (est.)Phase 2 · VS-7375imp 7/10

Pipeline

Asset	Phase	Indication
VS-7375	Phase 2	Pancreatic Ductal Adenocarcinoma
avutometinib	Phase 3	Low Grade Serous Ovarian Cancer
avutometinib (VS-6766)	Phase 2	Low Grade Ovarian Serous Adenocarcinoma
avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel	Phase 2	KRAS Activating Mutation
Avutometinib (VS-6766) + Defactinib (VS-6063)	Phase 2	Low Grade Serous Ovarian Cancer
defactinib (VS-6063)	Phase 2	Non Small Cell Lung Cancer
avutometinib (VS-6766) and adagrasib	Phase 2	Non Small Cell Lung Cancer
avutometinib and sotorasib	Phase 2	Non Small Cell Lung Cancer
avutometinib (VS-6766) and Defactinib	Phase 2	Non Small Cell Lung Cancer
cetuximab	Phase 2	Pancreatic Ductal Adenocarcinoma (PDAC)

Price & technical context

3-month

-18.9%

6-month

-40.3%

12-month

+4.9%

52-wk range

$3.45–$10.77

vs 50-day MA

-0.7%

vs 200-day MA

-33.5%

Realized vol

77.9%

Max drawdown

-68.0%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VSTM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.